MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS AND EXECUTIVE VICE PRESIDENT, HEAD OF EUROPE & REST OF WORLD 

February 10, 2016

MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS AND EXECUTIVE VICE PRESIDENT, HEAD OF EUROPE & REST OF WORLD 

London (United Kingdom) – Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced the appointment of Michele Antonelli  as President of  Stallergenes SAS and Executive Vice President, Head of Europe & Rest of World (excluding the Americas). He is succeeding Christian Chavy in these positions.

Michele has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in both manufacturing and commercial. He joined Stallergenes SAS in November 2015 as Executive Vice President, Head of International Operations. Michele previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities. Prior to joining UCB, Michele spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.

Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer, said:

Since joining us late last year, Michele has made an immediate, positive impact by assuming leadership for and overseeing the resolution of the operational disruptions caused by the implementation of our new IT system at our plant in Antony, France. Michele’s primary focus will be to deliver the value proposition of our state-of-the-art medicines to key Allergy Immunotherapy markets. He will also play a pivotal role in helping build our commercial organizational structure under the global Stallergenes Greer umbrella, ensure our commitment to remaining customer-centric, and help strengthen our culture dedicated to innovation and excellence in execution.”

“I would like to thank Christian for his contribution in bringing Stallergenes and Greer together – creating a new global allergy company – and helping expand access to our therapies for patients suffering with allergies in Europe and beyond. I wish him the best in his future endeavours.”